Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production could enhance economic stability and healthcare affordability.

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

EAST RUTHERFORD, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

ESTEVE CDMO, a global CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, began a $15.5 ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.